Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559300 | 0.86 | F2R (0.52) | F2RSLC6A3SLC6A2SLC6A4HTT | |
| SCHEMBL499535 | 0.78 | RIPK1 (0.38) | SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL7315171 | 0.78 | TACR2 (0.45) | — | |
| SCHEMBL756561 | 0.77 | TACR2 (0.46) | — | |
| SCHEMBL1690586 | 0.77 | F2R (0.41) | F2RSLC6A3SLC6A2SLC6A4HTT | |
| SCHEMBL4870085 | 0.77 | TACR2 (0.46) | — | |
| SCHEMBL1690588 | 0.77 | F2R (0.41) | F2RSLC6A3SLC6A2SLC6A4HTT | |
| SCHEMBL17267504 | 0.77 | RIPK1 (0.49) | LMNA | |
| SCHEMBL759265 | 0.76 | TACR2 (0.44) | — | |
| SCHEMBL8770867 | 0.76 | ALDH1A1 (0.42) | F2RSLC6A3HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007063086-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | HRH2, PROKR2, BDKRB2 | F2R 351/4885SLC6A3 2380/4885SLC6A2 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.